⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL11813638 | 0.97 | POLB (0.42) | — | |
| SCHEMBL16181475 | 0.97 | POLB (0.42) | — | |
| SCHEMBL806009 | 0.84 | — | — | |
| SCHEMBL8283698 | 0.84 | GNAI3 (0.43) | — | |
| SCHEMBL22140602 | 0.83 | DRD2 (0.39) | — | |
| SCHEMBL968058 | 0.82 | GNAO1 (0.52) | — | |
| SCHEMBL8431187 | 0.80 | GNAO1 (0.55) | — | |
| SCHEMBL22222479 | 0.80 | GNAO1 (0.55) | — | |
| SCHEMBL10584652 | 0.80 | GNAO1 (0.55) | — | |
| SCHEMBL17526500 | 0.80 | GNAO1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313546-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2025-10-09 | — | — | US | claimed |
| EP-4522588-A1 | NUCLEIC ACID BINDERS | University of Strathclyde (GB) | 2025-03-19 | — | — | EP | claimed |
| CN-119585239-A | Nucleic acid binding agents | 斯特拉斯克莱德大学 | 2025-03-07 | — | — | CN | claimed |
| WO-2023218194-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2023-11-16 | — | — | WO | claimed |
| CN-113087684-B | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-06-21 | — | — | CN | claimed |
| CN-113087684-A | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2021-07-09 | — | — | CN | claimed |
| US-20250313546-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2025-10-09 | — | — | US | disclosed |
| EP-4522588-A1 | NUCLEIC ACID BINDERS | University of Strathclyde (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119585239-A | Nucleic acid binding agents | 斯特拉斯克莱德大学 | 2025-03-07 | — | — | CN | disclosed |
| WO-2023218194-A1 | NUCLEIC ACID BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| CN-113201020-B | Preparation method of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2006050054-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-0958817-A1 | COMPOSITION CONTAINING DIARYLALKANE DERIVATIVE AS THE ACTIVE INGREDIENT FOR TREATING OR PREVENTING PANCREATITIS | SANKYO COMPANY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |